Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels

Leukemia and Lymphoma

Volumn 43, Issue 5, 2002, Pages 989-999

  Mainwaring, M G ^e   Rimsza, L M ^a   Chen, S F ^b   Gomez, S P ^b   Weeks, F W ^c   Reddy, V ^d   Lynch, J ^d   May, W S ^d   Kahn, S ^d   Moreb, J ^d   Leather, H ^d   Braylan, R ^a   Rowe, T C ^e   Finiewicz, K J ^d   Wingard, J R ^d  

^a Division of Hematopathology   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Vero Beach Oncology   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e Department of Pharmacology ^*

Author keywords

Refractory acute leukemia; Sequential chemotherapy; Topoisomerase II; Topotecan

Indexed keywords

ANTHRACYCLINE; CYTARABINE; DNA FRAGMENT; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GYRASE INHIBITOR; ISOENZYME; MITOXANTRONE; TOPOTECAN;

ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; BACTEREMIA; BLAST CELL; BLOOD TOXICITY; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DIARRHEA; DRUG EFFICACY; DRUG POTENTIATION; ERYTHROCYTE; FEBRILE NEUTROPENIA; FEMALE; HEART ARRHYTHMIA; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA REMISSION; LEUKOCYTE; MALE; MUCOSA INFLAMMATION; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SCORING SYSTEM; SEQUENTIAL ANALYSIS; THROMBOCYTE COUNT; VOMITING;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DNA FRAGMENTATION; DNA TOPOISOMERASES, TYPE II; ENZYME INDUCTION; ETOPOSIDE; FEMALE; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; MITOXANTRONE; TOPOTECAN;

EID: 18344395132     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190290021339     Document Type: Article

References (36)

1. "Acute myeloid leukemia"
2. "Current therapy and outcome of patients with relapsed acute myeloid leukemia"
3. "Topoisomerase II levels and drug sensitivity in adult Acute Myelogenous Leukemia"
4. "Relationship of DNA topoisomerase IIα and β expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines"
5. "MDR1 MRP, topoisomerase II alpha/beta, and cyclin A gene expression in acute and chronic leukemias"
6. "Topoisomerase II activities in AML blasts and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines"
7. "A two-step timed sequential treatment for acute myelocytic leukemia"
8. "Cures of leukemia with aggressive postremission treatment: An update of timed sequential therapy (Ac-D-Ac)"
9. "Cure of acute myelocytic leukemia in adults: A reality"
10. "A rationale for sequential high-dose chemotherapy of leukemia timed to coincide with induced tumor proliferation"
11. "Development of a cell kinetic approach to curative therapy of acute myelocytic leukemia in remission using the cell cycle-specific drug 1-beta-D-arabinofuranosylcytosine in a rat model"
12. "Two-cycle timed-sequential chemotherapy for adult acute nonlymphocytic leukemia"
13. "Growth response of residual leukemia after initial drug therapy"
14. "Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: A report from the children's cancer group"
15. "Sequential induction or double induction chemotherapy increases disease free survival compared to "3+7" chemotherapy in less than 50 years adults with acute myeloid leukemia (AML)"
16. "Mitoxantrone, etoposide, and intermediate-dose cytarabine: An effective and tolerable regimen for the treatment of refractory acute myeloid leukemia"
17. "Phase I study of topotecan, a new topisomerase inhibitor, in patients with refractory or relapsed acute leukemia"
18. "Phase I and pharmacodynamic study of the topoisomerase I inhibitor topotecan in patients with refractory acute leukemia"
19. "Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia"
20. "Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia"
21. "Topoisomerase II levels and DNA fragmentation of leukemia blasts from patients treated with timed sequential chemotherapy [abstract]"
22. "Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: A National Cancer Institute of Canada Clinical Trials Group Study"
23. "Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study"
24. "Topotecan increases topoisomerase II alpha levels and sensitivity to treatment with etoposide in schedule-dependent process"
25. Topotecan-induced topoisomerase IIα expression increases the sensitivity of the K562 cell line to subsequent etoposide plus mitoxantrone treatment
26. "Evaluation of topotecan and etoposide for non-Hodgkin lymphoma: Correlation of topoisomerase-DNA complex formation with clinical response"
27. "Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in Acute Myeloid leukemia"
28. "Limiting sampling models of topotecan pharmacokinetics"
29. "Phase I pharmacologic study of topotecan: A novel topoisomerase inhibitor"
30. "Mitoxantrone in the treatment of acute myelogenous leukemia: A review"
31. "A phase III comparison of high dose ARA-C versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute leukemia. A Southwest Oncology Group Study"
32. "The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia"
33. "High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refactory acute leukemia. Results of a clinical phase II study"
34. "Combination of mitoxantrone and VP-16 in refractory AML-an active and well-tolerated regimen"
35. "Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins"
36. "Induction of DNA strand breaks associated with apoptosis during treatment of leukemias"